The cytosine analogues 5-azacytidine and 5-aza-2 0 -deoxycytidine are currently the most advanced drugs for epigenetic cancer therapy. Both drugs function as DNA methyltransferase (DNMT) inhibitors and lead to the reactivation of epigenetically silenced tumour suppressor genes. However, not much is known about their target sequence specificity and their possible side effects on normally methylated sequences such as long interspersed nuclear element (LINE)-1 retroelements. It has been shown that demethylation and activation of the LINE-1 antisense promoter can drive the transcription of neighbouring sequences. In this study, we show that demethylation of the colon carcinoma cell line HCT116, either by treatment with DNMT inhibitors or by genetic disruption of the major DNMTs, induces the expression of an illegitimate fusion transcript between an intronic LINE-1 element and the proto-oncogene cMet (L1-cMet). Similar findings were also obtained with myeloid leukaemia cells, an established cellular model for the approved indication of azacytidine and decitabine. Interestingly, upregulation of L1-cMet transcription resulted in reduced cMet expression, which in turn led to decreased cMet receptor signalling. Our results thus provide an important paradigm for demethylation-dependent modulation of gene expression, even if the promoter of the corresponding gene is unmethylated.
Introduction
The development of cancer is accompanied by changes in the expression of key regulatory genes. This dysregulation is caused by genetic and epigenetic alterations that cooperate at all stages of tumourigenesis. Epigenetic alterations in cancer are complex (Ehrlich, 2002) , and considerable efforts have focused on the promoter hypermethylation of tumour suppressor genes, which is associated with transcriptional silencing (Esteller, 2007) . These epimutations have been described in numerous cancers and for various tumour suppressor genes and other 'gatekeeper genes' that are involved in the regulation of cell proliferation or survival (Feinberg et al., 2006; Jones and Baylin, 2007) .
In contrast to genetic mutations that are inherited passively through DNA replication and are therefore irreversible, epigenetic mutations are reversible. This reversibility established the use of DNA methyltransferase (DNMT) inhibitors as an attractive concept for cancer therapy (Lyko and Brown, 2005) . The cytosine analogues 5-azacytidine (azacytidine) and 5-aza-2 0 -deoxycytidine (decitabine) function as DNMT inhibitors and have been shown to effectively demethylate DNA and reverse gene silencing in vitro (Chuang et al., 2005; Stresemann et al., 2006) . In addition, azanucleosides are currently the most advanced drugs for epigenetic cancer therapy (Egger et al., 2004; Issa and Kantarjian, 2009 ). Both drugs are registered for the treatment of myelodysplastic syndrome, after they have shown considerable clinical benefit in large clinical trials (Silverman et al., 2002; Kantarjian et al., 2006) .
After incorporation into DNA, decitabine and azacytidine lead to DNA demethylation by covalent trapping and subsequent depletion of DNMTs (Santi et al., 1984; Weisenberger et al., 2004) . Therefore, decitabine-and azacytidine-induced demethylation is a passive mechanism linked to the DNA replication process, thus affecting only dividing cells, such as highly proliferating cancer cells. In cell culture models, both drugs have the ability to reduce cytosine methylation significantly, although the efficiency can vary between cell lines (Chuang et al., 2005; Stresemann et al., 2006) . Several studies also showed genome-wide and gene-specific demethylating activity of azanucleoside drugs in myelodysplastic syndrome patients undergoing epigenetic therapy (Mund et al., 2005; Gore et al., 2006; Yang et al., 2006; Stresemann et al., 2008) .
Drug-induced demethylation is primarily targeted at cancer-specific epigenetic mutations, including hypermethylated tumour suppressor genes (Esteller, 2007) . However, decitabine and azacytidine are not specific for epigenetic mutations and also demethylate other methy-lated loci in the genome. More specifically, it has been shown that both drugs can cause significant demethylation of long interspersed nuclear element (LINE)-1 elements in various experimental and clinical settings (Yang et al., 2004) . Although the majority of LINE-1 in the human genome have undergone mutational inactivation, some have retained the ability to retrotranspose. In addition, it has been shown that the LINE-1 antisense promoter (ASP), when activated, can drive the transcription of neighbouring genes (Speek, 2001) . A recent study has suggested that azacytidine may activate the transcription of such illegitimate fusion transcripts from the LINE-1 ASP (Cruickshanks and Tufarelli, 2009 ). However, the methylation and expression changes observed in this study seemed very small and their functional significance was not investigated.
The LINE-1 inserted in the second intron of the cMet proto-oncogene represents an attractive model for studying the 'off-target' effects of drug-induced DNA demethylation. The element is closely associated with a prominent oncogene and its orientation allows the generation of a novel cMet transcript from the antisense LINE-1 promoter. It has been suggested that DNA demethylation might increase cMet expression in chronic myeloid leukaemia cell lines (Roman-Gomez et al., 2005) , but the expression of the fusion transcript was not specifically investigated in this study. We have now performed a detailed analysis of the epigenetic regulation of the LINE1-cMet ASP. Our results show that this promoter is heavily methylated in most human tissues. Loss of DNA methylation caused significant upregulation of the L1 ASP-driven transcript, which coincided with reduced cMet expression and reduced Met signalling. These effects could also be observed when cancer cells were incubated with nanomolar doses of decitabine over an extended period of time. Our results thus provide an important example for demethylation-induced modulation of a cancer pathway that is not related to the traditionally described reactivation of epigenetically silenced tumour suppressor genes.
Results

L1
-cMet is a fusion transcript between the cMet gene and an intronic LINE-1 (L1). Human cMet encodes for the hepatocyte growth factor receptor, a receptor tyrosine kinase that has been shown to function as a proto-oncogene for many forms of cancer. The human cMet gene consists of 21 exons and contains an intronic L1 element between the second and third exon ( Figure 1a ). Similar to other full-length human L1 elements, the 5 0 UTR of this L1 element also harbours two promoters: a sense promoter that drives transcription of the L1 element and an ASP that drives transcription from the opposite strand and into the cMet locus (Figure 1a) .
The 5 0 UTR of the L1-cMet element contains a welldefined CpG island encompassing 350 bp of DNA sequence (Figure 1a) . Using combined bisulphite restriction analysis (COBRA), we analysed the methylation status of this CpG island in six different normal human tissues (blood, skin, lung, placenta, brain and colon). For comparisons, we also included a general LINE-1 COBRA assay, a COBRA assay for the heterochromatic chromosome 1 satellite 2 repeats and a third COBRA assay for the tumour suppressor gene TIMP-3. As expected for normal healthy tissues, TIMP-3 was found to be completely unmethylated in all tissues analysed. LINE-1 and satellite repeats were found to be heavily methylated in all tissues except placenta and skin ( Figure 1b) . Similarly, the cMet-specific L1 element (L1-cMet) was heavily methylated in all tissues, with the exception of placenta (Figure 1b) . Placenta-specific hypomethylation of L1-cMet could also be confirmed by bisulphite sequencing (Figure 1c ) and is consistent with the general genome hypomethylation of this tissue (Novakovic et al., 2010) . Together, these results indicate that the L1-cMet CpG island is heavily methylated in the majority of human tissues.
To determine whether the DNA methyltransferase inhibitors decitabine and azacytidine are able to demethylate L1-cMet, the human colon cancer cell line HCT116 was treated for 72 h with different concentrations of decitabine and azacytidine (0.1, 1 and 10 mM). Again, L1-cMet was heavily methylated in untreated control cells and drug-induced demethylation was readily detectable by COBRA ( Figure 2a ). All three concentrations of decitabine were sufficient to reduce the DNA methylation level of L1-cMet, whereas no demethylation was detectable with 10 mM azacytidine. Assays for L1 elements and chromosome 1 satellite 2 repeats were included as a control for the treatment and confirmed the demethylating effects of decitabine and azacytidine (Figure 2a) . Finally, bisulphite sequencing of L1-cMet confirmed the drug-dependent demethylation and showed a reduction from 99% methylation in control cells to 59% in cells treated with 1 mM decitabine and to 22% in cells treated with 1 mM azacytidine ( Figure 2b) .
In subsequent experiments, we also analysed whether the decitabine-and azacytidine-dependent demethylation induces the L1-cMet fusion transcript. Transcriptional analysis using real-time (RT)-PCR of drugtreated HCT116 cells confirmed the induction of a L1-cMet transcript in a dose-dependent manner. We observed the highest level of L1-cMet transcription on treatment with 10 mM decitabine (about sevenfold in comparison with untreated control cells, Figure 2c ). For azacytidine treatment, the highest L1-cMet mRNA levels were observed after a dose of 1 mM and returned to baseline levels after treatment with 10 mM azacytidine ( Figure 2c ). This result is consistent with the absence of demethylating effects at high azacytidine concentrations (see Figure 2a) .
As decitabine and azacytidine are primarily used for the treatment of myeloid leukaemia patients, we also analysed their effects on L1-cMet in ML-1 and HL-60 myeloid leukaemia cell lines. Cells were treated for 72 h with different concentrations of decitabine or azacytidine, ranging from 30 nM to 3 mM. COBRA analysis of L1-cMet methylation suggested pronounced methylation in untreated cells and concentration-dependent demethylation for both drugs and in both cell lines ( Figure 3a ). Bisulphite sequencing showed partial methylation of L1-cMet in ML-1 cells and complete methylation in HL-60 cells (Figure 3b ). Treatment with 3 mM decitabine or azacytidine induced only minor changes in ML-1 cells (Figure 3b ). However, pronounced demethylation could be observed in HL-60 cells after decitabine treatment (Figure 3b ). Quantitative RT-PCR analysis revealed that untreated ML-1 cells did not express L1-cMet, and only very minor effects could be observed after decitabine or azacytidine treatment ( Figure 3c ). However, a strong concentration-dependent induction of L1-cMet transcription could be observed in decitabine-treated HL-60 cells and, to a lesser extent, in azacytidine-treated HL-60 cells ( Figure 3c ). Together, these results illustrate the ability of demethylating drugs to induce illegitimate transcription events in a model which is closely related to the approved indication of decitabine and azacytidine.
The effects of decitabine and azacytidine are not restricted to DNA demethylation. For example, it has cMet illegitimate transcription B Weber et al been shown that decitabine and azacytidine have cytotoxic effects and induce DNA damage (Juttermann et al., 1994; Palii et al., 2007) . To further confirm the role of DNA demethylation in the induction of L1-cMet transcription, we used a HCT116 cell line with targeted deletions in DNMT1 and DNMT3B genes (Rhee et al., 2002) . These double knockout (DKO) cells have a largely demethylated genome and we confirmed complete demethylation of L1-cMet by bisulphite sequencing ( Figure 4a ). Quantitative RT-PCR analysis of cDNA from these cells confirmed that L1-cMet demethylation is associated with robust (sevenfold) transcriptional upregulation of the L1-cMet fusion transcript ( Figure 4b ). Given that epigenetic control is known to be mediated by an interplay between DNA methylation and covalent histone modifications, we were also interested in the histone modification patterns of the L1-cMet regulatory region. Therefore, chromatin immunoprecipitation experiments were performed in HCT116 and DKO cells using specific antibodies against dimethylated histones H3K4 and H3K9, acetylated histones H3 and H4 and the early elongating polymerase II, followed by quantitative RT-PCR. The results showed that the activating H3K4 dimethylation and H3 and H4 acetylation marks were significantly enriched at L1-cMet in DKO cells when compared with the original HCT116 cell line. In contrast, the repressive H3K9 dimethylation mark remained unchanged at background levels in both cell lines (Figure 4c ). In addition, in agreement with the finding of L1-cMet activation, we detected a slight increase in the occupancy of polymerase II at L1-cMet in DKO cells in comparison with HCT116 cells (Figure 4c ). These results are consistent with the DNA methylation changes observed at the L1-cMet ASP CpG island and further illustrate the epigenetic regulation in this region.
To address the functional significance of the L1-cMet transcript, we analysed cMet expression in DKO cells and used western analysis to compare cMet protein levels between HCT116 cells and DKO cells. The results showed a significant reduction in cMet protein levels in demethylated DKO cells (Figure 5a ). Accordingly, quantitative RT-PCR analysis indicated that in DKO cells the levels of the normal cMet transcript are considerably lower (Figure 5b ), suggesting that this reduction in cMet is caused by reduced expression of the normal cMet transcript. The cMet promoter is associated with a large CpG island encompassing 810 bp of DNA sequence, which raised the possibility that this expression change is related to a change in cMet promoter methylation. However, COBRA analysis indicated that the cMet promoter CpG island is completely unmethylated in control HCT116 and in DKO cells (Figure 5c ), thus suggesting that cMet is not directly regulated by DNA methylation. We also On decitabine treatment, we observed a significant decrease in cMet RNA levels in HCT116 and ALL1 (acute lymphoblastic leukaemia) cells and, to a lesser extent, in WI-38 and MCF7 cells (Figure 5d ). Interestingly, downregulation of cMet closely correlated with the degree of L1-cMet induction (Figure 5e ). In HCT116 and ALL1 cells, L1-cMet was undetectable and became significantly induced on decitabine treatment. In WI-38 cells, drug-dependent L1-cMet induction seemed substantially weaker, and in MCF-7 cells, L1-cMet was already expressed in untreated cells and no upregulation was observed on drug treatment (Figure 5e ). Our results thus suggest that induction of the L1-cMet fusion transcript may interfere with normal cMet expression.
To confirm that the downregulation of cMet has functional consequences on cMet signalling, we stimulated HCT116 and DKO cells with the cMet ligand hepatocyte growth factor (HGF). HGF binding leads to cMet autophosphorylation and concomitant activation of the receptor. Activation of cMet results in the recruitment of signal transducers, which in turn activate different signalling branches, including the ERK/mitogen-activated protein kinase pathway. As a consequence, cMet activation initiates a complex network of multiple biological responses that collectively induce invasive growth (Birchmeier et al., 2003) . Immunoblotting with antibodies against activated phospho-cMet and the downstream signalling component phospho-ERK revealed a significant reduction of both proteins in DKO cells (Figure 6a ). This suggested that DNA demethylation caused induction of the illegitimate L1-cMet transcript, which results in reduced Met signalling in HCT116 cells. To determine whether the reduced Met signalling in methylation-deficient cells is due to low cMet levels, we transiently transfected DKO cells with a cMet overexpression construct. Western blot analysis showed robust levels of cMet expression in transfected DKO cells that were similar to or higher than those observed in HCT116 cells (Figure 6b ). More important, when transfected DKO cells were stimulated with HGF, and Met signalling was analysed, the results showed a strong increase in phospho-cMet and phospho-ERK levels ( Figure 6c ). Thus, these results further underscore the significance of the local epigenetic regulation at the cMet locus for downstream cMet signalling.
To further confirm cMet downregulation in the context of drug-induced demethylation, we treated HCT116 cells for an extended period of time (13 days) with low doses (0.2 mM) of decitabine or azacytidine. COBRA analysis of L1-cMet indicated strong demethylation by 0.2 mM decitabine, but only minor demethylation effects by azacytidine (Figure 7a ). Similar demethylation was also observed in a COBRA analysis of chromosome 1 satellite 2 repeats (Figure 7a ), which represents a surrogate marker for the global DNA methylation level (Mund et al., 2005) . In agreement with these findings, quantitative RT-PCR showed that decitabine, but not azacytidine, led to a significant transcriptional activation of L1-cMet (Figure 7b) . Similarly, the long-term treatment with decitabine strongly reduced cMet protein levels, whereas azacytidine had only minor effects (Figure 7c ). These results suggest that, under these conditions, decitabine is able to induce drug-dependent demethylation of L1-cMet, associated with upregulation of the illegitimate L1-cMet fusion transcript and simultaneous downregulation of cMet protein levels. Unlike decitabine, the-long term treatment of HCT116 cells with 0.2 mM azacytidine failed to induce L1-cMet transcription (Figure 7b ). This may be due to the selection of resistant cells during prolonged drug incubation (Vesely et al., 1967; Qin et al., 2009 ). Alternatively, the azacytidine 
Discussion
The induction of genome-wide hypomethylation by the administration of demethylating drugs is a therapeutic approach with increasing importance for the clinical treatment of human cancers (Issa and Kantarjian, 2009 ). The aim of epigenetic therapy with decitabine and azacytidine is to reactivate aberrantly silenced tumour suppressor genes. However, DNMT inhibitors function nonspecifically and can potentially reactivate every gene silenced by DNA methylation. Although there are many studies suggesting that azanucleoside drugs preferentially reactivate genes that are aberrantly hypermethylated and silenced in cancer (Mund et al., 2006) , not much is known about the possible side effects of epigenetic therapy on normally methylated sequences such as retroelements and other transposable elements. The transcriptional changes induced by DNA hypomethylation have been investigated in considerable detail (Gius et al., 2004; Schuebel et al., 2007) . Although these studies have uncovered a variety of epigenetically silenced genes, they have also shown that demethylation-induced expression changes are surprisingly complex. In this context, it is important to notice that DNA methylation is a major mechanism used for the epigenetic silencing of retroelements (Schulz et al., 2006) , and that it has been shown that DNA hypomethylation can lead to the activation and transposition of endogenous transposable elements (Walsh et al., 1998; Howard et al., 2008) . Consequently, these elements also have the potential to induce the illegitimate transcription of neighbouring sequences when incorporated in or in the vicinity of genes.
LINE-1 are heavily methylated in the human genome and thus represent a bona fide target for demethylating drugs (Yang et al., 2004) . Furthermore, a bioinformatical approach revealed that transcripts derived from the ASP of LINE-1 are highly represented in expressedsequence tag databases (Nigumann et al., 2002) . In this study, we showed the demethylation-dependent induction of an illegimate transcript originating from an intronic L1-ASP located in the cMet gene (L1-cMet). This effect was seen in a variety of cell types including HL-60 myeloid leukaemia cells, an established cellular model for the approved indication of azacytidine and decitabine. In addition, drug-induced activation of illegitimate transcription was also observed at additional retroelement promoters with the potential to produce fusion transcripts between retroelements and neighbouring sequences in HL-60 cells (Weber B, unpublished data). Together, our results thus suggest that the epigenetic activation of illegitimate fusion transcripts may be a relatively common consequence of drug-induced demethylation in human cancer cell lines and, potentially, in patients undergoing demethylation therapy.
More important, we also observed that L1-cMet activation was associated with reduced activity of the conventional cMet promoter, which resulted in decreased cMet receptor signalling. This correlation was further strengthened by the observation that cells with no detectable L1-cMet induction did not show a drugdependent reduction in cMet expression. The exact mechanism by which the induction of L1-cMet interferes with cMet expression remains unknown and will have to be determined in future studies. We are currently considering three possible mechanisms to explain the connection between L1-cMet activation and cMet (Jones et al., 1998) , thus resulting in transcriptional downregulation of cMet.
(ii) Overlapping transcription is thought to cause transcriptional interference (Martianov et al., 2007; Mazo et al., 2007) . Accordingly, initiation of transcription from the downstream L1-ASP may interfere with elongation of the original Met transcript. (iii) If the L1 sense promoter is also induced, a Met antisense transcript may be formed that could negatively regulate cMet expression by RNA interference. Regardless of the precise mechanism of cMet downregulation, our results provide an important paradigm for how DNA demethylation can change the expression of genes, even if the actual promoter of the corresponding gene is unmethylated. cMet illegitimate transcription B Weber et al (Invitrogen, Darmstadt, Germany) , 100 u/ml penicillin and 100 mg/ml streptomycin (Pen/Strep, Invitrogen). MCF7 breast cancer cells were cultured in Dulbecco's Modified Eagle's Medium supplemented with 10% FCS, Pen/Strep and 2 mM glutamine. WI-38 primary lung fibroblasts were cultured in MEM-Eagle (Sigma, Munich, Germany) with 10% FCS, Pen/ Strep, 2 mM glutamine and 1 mM sodium pyruvate. HL-60, ML-1 and acute lymphoblastic leukaemia-1 cells were cultured in RPMI 1640 medium supplemented with 10% FCS and Pen/ Strep. 2 0 -deoxy-5-azacytidine (Sigma) and 5-azacytidine (Sigma) were added in the concentrations indicated, after a seeding period of 24 h and the cells were harvested 72 h later. For longterm treatments, cells were split into fresh medium containing decitabine/azacytidine every 3 days and were harvested after 13 days. For stimulation, cells were seeded in McCoy's 5a medium supplemented with 10% FCS. After 24 h, the FCScontaining medium was replaced by medium without FCS and an additional 24 h later, the cells were stimulated by adding 50 ng/ml HGF (R&D Systems, Wiesbaden, Germany) for 10 min at 37 1C. Cells were washed with cold phosphate-buffered saline and collected by centrifugation for protein preparation.
Materials and methods
Cell
Transfection experiments DKO cells were plated in 10 cm dishes and transiently transfected with different concentrations of full-length human cMet in a pTRex-DEST30 vector (imaGenes ORF Expression Clone IOH36570-pT-Rex-DEST30) or with vector alone using Effectene Transfection Reagent (Qiagen, Hilden, Germany). After 48 h, cells were washed once with phosphate-buffered saline and harvested.
DNA methylation analysis
Genomic DNA was isolated using the DNeasy Blood and Tissue kit (Qiagen) according to the manufacturer's instructions. For gene-specific methylation analysis using COBRA, genomic DNA was treated with sodium bisulphite using an EpiTect Bisulfite kit (Qiagen), followed by PCR amplification with the following cycling conditions: 35 cycles of 95 1C for 30 s, at 51-60 1C (see Supplementary Table 1) for 30 s and at 72 1C for 45 s. Primer sequences are provided in Supplementary Table 1 . The PCR products were separated on agarose gels, gel extracted with the Gel Extraction kit (Qiagen) and digested as follows: cMet, chromosome 1 satellite 2 and LINE-1 with HinfI; L1-cMet and TIMP-3 with BstUI. Digested PCR products were then separated on agarose gels. For bisulphite sequencing, the PCR products were gel extracted and cloned using the TOPO TA cloning kit (Invitrogen) according to the manufacturer's instructions.
RT-PCR analysis
Total RNA was isolated using the RNeasy Mini kit (Qiagen). Cell lysates were homogenized with QIAshredder spin columns (Qiagen), and an optional on-column DNase digestion step using the RNase-Free DNase set (Qiagen) was included. Total RNA (2-5 mg) was reverse transcribed with the Superscript III First-Strand Synthesis system (Invitrogen) or ImProm-II (Promega, Mannheim, Germany) using random hexanucleotide primers. For RT-PCR primer sequences, see Supplementary Table 1 . Levels of transcription were normalized to lamin B, except for data in Figure 4d , which were normalized to GAPDH. Quantitative RT-PCR was performed with the LightCycler 480 system (Roche, Mannheim, Germany) using the QuantiFast SYBR Green PCR kit (Qiagen), according to the manufacturer's instructions or, for Figure 4d , with an ABI PRISM 7900HT Real-Time PCR System using SYBR Green PCR Master Mix (Applied Biosystems, Darmstadt, Germany). For conventional semiquantitative RT-PCRs, the following cycling conditions were used: 32 cycles at 95 1C for 30 s, at 60 1C for 30 s and at 72 1C for 45 s. The PCR products were visualized on agarose gels.
Chromation immunoprecipitation
Chromatin was prepared as described previously (Boyd and Farnham, 1999) . Cells (8-10 Â 10 6 ) were fixed at 4 1C for 10 min. After lysis, samples were cooled on ice and sonicated in the presence of glass beads (150-212 mm; Sigma) in 8-10 cycles of 30 s duration, followed by pauses of 30 s. Sonicates were centrifuged for 10 min at 14 000 g at 4 1C, diluted to 0.2% SDS with dilution buffer (10 mM Tris-HCl pH 8, 0.5 mM EGTA, 1% Triton X-100 and 140 mM NaCl), then aliquoted and used directly for immunoprecipitation. Immunoprecipitation was performed as described (Breiling et al., 2001) , with the following modifications. For antibody binding, protein G magnetic beads (Dynabeads, Invitrogen) were used (10 ml bead solution per reaction). For preblocking, the beads were washed twice in fresh block solution (0.5% bovine serum albumin (w/v) in phosphate-buffered saline; 1 ml block solution per 100 ml beads) and then incubated in block solution overnight on a rotating platform at 4 1C. The beads were washed twice and resuspended in dilution buffer (30 ml dilution buffer per 10 ml beads). For each immunoprecipitation reaction, 30 ml of beads was used. The following antibodies were used: dimethyl-H3K9 (Abcam, Cambridge, UK), dimethyl-H3K4 (Millipore), acetyl-H3 (Millipore), acetyl-H4 (Millipore) and RNA Pol II CTD repeat YSPTSPS (Abcam). After antibody incubation (overnight at 4 1C) and washing (Breiling et al., 2001) , beads were incubated with 210 ml elution buffer (50 mM Tris-HCl pH 8, 10 mM EDTA, 1% SDS) and eluted at 65 1C for 15 min with brief vortexing intervals. The samples and a nontreated aliquot of chromatin (input) were incubated overnight at 65 1C to reverse crosslinks. Each reaction was diluted with 200 ml TE, treated with RNase (0.2 mg/ml) for 2 h at 37 1C and then subjected to 0.5 mg/ml proteinase K and incubated for an additional 3 h at 50 1C. DNA was purified using the DNeasy Blood and Tissue kit (Qiagen) according to the manufacturer's protocol. For chromatin immunoprecipitation analysis, we specifically detected the cMet-L1 element using the following primers: sense 5 0 -CAATATTCGGGTGGGAGTGA-3 0 , antisense 5 0 -GCTTATCCACGGAGCCAAG-3 0 .
Western blot analysis
Whole-cell lysates were prepared with RIPA buffer using standard procedures. For lysates from HGF-stimulated cells, the lysis buffer was supplemented with phosphatase inhibitors NaF and NaV. For each sample, 70 mg of protein was fractionated on an 8% sodium dodecyl sulphate-polyacrylamide gel and transferred onto PVDF membranes. Membrane blocking, washing and antibody incubation were performed with 5% milk powder in phosphate-buffered saline. The following primary antibodies were used: Met (C-12: sc-10, Santa Cruz, Santa Cruz, CA, USA; 1:300), phospho-Met (Tyr1234/1235 3D7, Cell Signaling, Danvers, MA, USA; 1:1000); phospho-Erk1/2 (Thr202/Tyr204 910L, Cell Signaling; 1:1000) and b-actin (Abcam 8226, Abcam; 1:10 000). Primary antibodies were stained with horse-radish peroxidaseconjugated anti-rabbit or anti-mouse secondary antibodies (Jackson Immuno Research, West Grove, PA, USA, 1:10,000). Protein bands were visualized by chemiluminescence (Perkin Elmer, Rodgau, Germany) and X-ray imaging film.
